News
The FDA investigates 65 additional cases of nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in renally impaired patients.
Gadopiclenol carries a Boxed Warning associated with an increased risk of nephrogenic systemic fibrosis among patients with impaired elimination of the drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback